MedWorm: Psoriasis

Health news: Pomegranates can speed up labour, new psoriasis drug offers greater relief and a dose of herbs could banish flu

the Mail online | Health — Tue, 09 Feb 2010 08:46:22 +0100

Pomegranates could help speed up childbirth - and may reduce the number of emergency Caesarean sections performed as a result of long labour. (Source: the Mail online | Health)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

SMC accepts restricted use of ustekinumab (Stelara®) for psoriasis

NeLM - Drug Specific Reviews — Mon, 08 Feb 2010 00:00:00 +0100

Source: Scottish Medicines Consortium (SMC) Area: Evidence > Drug Specific Reviews Following a full submission, the Scottish Medicines Consortium (SMC) has accepted ustekinumab (Stelara®) for restricted use within NHS Scotland for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen and UVA treatment (PUVA). Continued treatment should be restricted to patients who achieve a PASI 75 response within 16 weeks. This advice takes account of a Patient Access Scheme that improves the cost-effectiveness of ustekinumab, and is therefore dependent upon its continuing availability in NHS Scotland. The drug a...

Methotrexate enhances NBUVB treatment of psoriasis

MedWire News - Psoriasis — Sat, 06 Feb 2010 14:09:57 +0100

The combination of methotrexate and narrowband ultraviolet B phototherapy may offer psoriasis patients more rapid clinical improvement of their symptoms than narrowband ultraviolet B phototherapy alone, research suggests. (Source: MedWire News - Psoriasis)

Tailor Etanercept to Symptoms in Psoriasis and Psoriatic Arthritis (CME/CE)

MedPage Today Dermatology — Fri, 05 Feb 2010 12:43:02 +0100

The decision to use once-weekly or twice-weekly etanercept in patients with both psoriasis and psoriatic arthritis should be determined by the cutaneous and joint symptoms of the patient, researchers said. (Source: MedPage Today Dermatology)

Methotrexate enhances NBUVB treatment of psoriasis

MedWire News - Dermatology — Fri, 05 Feb 2010 00:00:00 +0100

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial

BMJ Online First — Wed, 03 Feb 2010 00:06:16 +0100

Objectives To compare the efficacy over 12 weeks of two different etanercept regimens in treating the skin manifestations of psoriasis in patients who also have psoriatic arthritis and to evaluate... (Source: BMJ Online First)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Efficacy of a far erythemogenic dose of narrow-band ultraviolet B phototherapy in chronic plaque-type psoriasis

The Journal of Dermatology — Wed, 03 Feb 2010 00:00:00 +0100

The aim of the present study was to examine the effect of far erythemogenic dose of narrow-band ultraviolet B (NB-UVB; starting dose at 35% minimal erythematous dose [MED]) on clinical response by measuring the severity, extent of disease and the changes in quality of life. Fifty patients with chronic plaque-type psoriasis were enrolled. Therapy was held for 3 days a week. The severity of the disease was assessed based on the Psoriasis Area and Severity Index (PASI) score and Dermatology Life Quality Index (DLQI) scores. The percentage improvement of PASI at 30 sessions was 68.99%. The improvement in DLQI scores at 30 sessions was 79.67%. Pearson correlation coefficients showed that PASI scores were not correlated with DLQI scores at the beginning of treatment (P = 0.330, r = 0.14), but af...

Comorbidities associated with psoriasis: An experience from the Middle East

The Journal of Dermatology — Wed, 03 Feb 2010 00:00:00 +0100

Recent studies suggest that psoriasis patients have higher rates of comorbidities. We sought to determine the prevalence of comorbidities and co-medications in our psoriasis patients. We conducted case-control study in 1835 patients with psoriasis vulgaris and age- and gender-matched cohort without psoriasis. Patients were examined for clinical characteristics of psoriasis, PASI scores, and data of age, sex, body mass index (BMI), smoking status, comorbidities, and co-medications were analysed for both patients and controls. We identified 1661 (92.8%) patients with mild to moderate psoriasis (PASI < 10) and 129 patient's (7.03%) with severe psoriasis (PASI > 10). Patients with psoriasis were more likely to be current smokers (51.34% vs 32.51% controls). Respective prevalence rates of risk ...

Etanercept in psoriasis: initial twice weekly treatment brings faster improvement to skin but not joints

NeLM - News — Wed, 03 Feb 2010 00:00:00 +0100

The objective of this study was to determine whether either regimen was superior in patients with both skin and joint symptoms. Participants were adults with active but stable moderate to severe psoriasis and active psoriatic arthropathy. They were randomised to etanercept 50mg once or twice weekly for 12 weeks, with matching placebo in the once weekly group to maintain blinding. After the 12 week study period, all received open-label once weekly etanercept for a further 12 weeks. Primary outcome was the proportion of participants who achieved "clear" or ... (Source: NeLM - News)

High Prevalence of Potential Drug-Drug Interactions for Psoriasis Patients Prescribed Methotrexate or Cyclosporine for Psoriasis: Associated Clinical and Economic Outcomes in Real-World Practice

Dermatology — Tue, 02 Feb 2010 23:00:00 +0100

Dermatology (DOI:10.1159/000275198) (Source: Dermatology)

Psoriasis treatment: Can fish oil supplements reduce symptoms?

MayoClinic.com Full Feed — Tue, 02 Feb 2010 06:00:00 +0100

Psoriasis treatment — Fish oil supplements may be helpful, but use caution. (Source: MayoClinic.com Full Feed)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Psoriasis treatment: Can fish oil supplements reduce symptoms?

MayoClinic.com - Ask a Specialist — Tue, 02 Feb 2010 06:00:00 +0100

Psoriasis treatment — Fish oil supplements may be helpful, but use caution. (Source: MayoClinic.com - Ask a Specialist)

Relationships between obesity and the clinical severity of psoriasis in Taiwan

Journal of the European Academy of Dermatology and Venereology — Tue, 02 Feb 2010 00:00:00 +0100

Conclusions In psoriasis patients, obesity is associated with a more severe disease, especially in men. Bodyweight control may be important for the management of psoriasis. (Source: Journal of the European Academy of Dermatology and Venereology)

Effect of cyclosporine on blood pressure

NeLM - Patient Safety — Tue, 02 Feb 2010 00:00:00 +0100

Source: Cochrane Library Area: Evidence > Medication Safety Abstract Background Cyclosporine is an immunosuppressive agent used for different autoimmune diseases. The official Canadian indications for cyclosporine are solid organ transplantation, bone marrow transplantation, psoriasis, rheumatoid arthritis and nephritic syndrome (e-CPS 2008). The expanding range of indications for cyclosporine therapy will lead to more patients receiving chronic therapy with possible side effects, hypertension being one of the most common. Therefore it is essential to know the magnitude of increase of blood pressure (BP) associated with cyclosporine in order to appropriately manage patients receiving the drug. Objectives The primary objective of this systematic review is to evaluate ...

The uses and properties of almond oil.

Complementary Therapies in Clinical Practice — Mon, 01 Feb 2010 00:00:00 +0100

Authors: Ahmad Z Almond oil [Oleum amygdalae] has long been used in complementary medicine circles for its numerous health benefits. Although no conclusive scientific data exists currently, almonds and almond oil have many properties including anti-inflammatory, immunity-boosting and anti-hepatotoxicity effects. Further, associations between almond oil and improved bowel transit have been made, which consequently reduces irritable bowel syndrome symptoms. Further, some studies show a reduced incidence of colonic cancer. Moreover, cardiovascular benefits have also been identified with almond oil elevating the levels of so-called 'good cholesterol', high-density lipoproteins (HDL), whilst it reduces low-density lipoproteins (LDL). Historically, almond oil had been used in Ancient Chinese...

IL-1 from epithelial cells fosters T-cell dependent skin inflammation.

The British Journal of Dermatology — Mon, 01 Feb 2010 00:00:00 +0100

Conclusion IL-1 secretion and the physical contact between keratinocytes and activated, infiltrating T-cells may be central for the development of chronic inflammatory skin conditions. PMID: 20128791 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Phosphodiesterase 7A inhibitor ASB16165 impairs proliferation of keratinocytes in vitro and in vivo.

European Journal of Pharmacology — Mon, 01 Feb 2010 00:00:00 +0100

Authors: Goto M, Kadoshima-Yamaoka K, Murakawa M, Yoshioka R, Tanaka Y, Inoue H, Murafuji H, Kanki S, Hayashi Y, Nagahira K, Ogata A, Nakatsuka T, Fukuda Y Excessive proliferation of epidermal keratinocytes is a typical aspect of chronic skin diseases such as psoriasis. In the present study, effect of phosphodiesterase 7A (PDE7A) inhibitor ASB16165 on proliferation of keratinocytes was investigated to examine the role of PDE7A in keratinocyte proliferation and the possible therapeutic relevance of PDE7A inhibition in psoriasis. Topical application of ASB16165 inhibited the increase of thickness of skin as well as epidermis in a skin inflammation model induced by repeated painting of 12-O-tetradecanoylphorbol-13-acetate (TPA) in a concentration-dependent manner. The ASB16165 treatment a...

The patient's journey: living with psoriasis - the doctors' perspective.

The British Journal of General Practice — Mon, 01 Feb 2010 00:00:00 +0100

Authors: Alexandroff AB, Johnston GA PMID: 20132723 [PubMed - in process] (Source: The British Journal of General Practice)

The patient's journey: living with psoriasis - the patient's perspective.

The British Journal of General Practice — Mon, 01 Feb 2010 00:00:00 +0100

Authors: Pickering H PMID: 20132722 [PubMed - in process] (Source: The British Journal of General Practice)

No increased cancer risk with coal tar treatment

MedWire News - Psoriasis — Sat, 30 Jan 2010 14:00:23 +0100

Researchers say that coal tar for the treatment of psoriasis and eczema should not be abandoned, after finding concerns of an associated increased risk for cancer are unfounded. (Source: MedWire News - Psoriasis)

Photoleukomelanoderma possibly caused by etretinate in a patient with psoriasis.

Acta Derm Venereol A... — Sat, 30 Jan 2010 10:22:03 +0100

Authors: Seishima M, Shibuya Y, Kato G, Watanabe K PMID: 20107735 [PubMed - in process] (Source: Acta Derm Venereol A...)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Skin pain and discomfort in psoriasis: an exploratory study of symptom prevalence and characteristics.

Acta Derm Venereol A... — Sat, 30 Jan 2010 10:22:03 +0100

In conclusion, pain and discomfort are more common and more severe in patients with psoriasis than previously estimated. PMID: 20107724 [PubMed - in process] (Source: Acta Derm Venereol A...)

Psoriasis and hypertension: a case-control study.

Acta Derm Venereol A... — Sat, 30 Jan 2010 10:22:03 +0100

Authors: Cohen AD, Weitzman D, Dreiher J In recent years, numerous reports have demonstrated an association between psoriasis and metabolic syndrome. However, some studies failed to demonstrate an association between psoriasis and hypertension. The aim of the present study was to examine the association between psoriasis and hypertension. Psoriasis patients of a health-maintenance organization were compared with enrollees without psoriasis regarding the prevalence of hypertension in a case-control study. The study included 12,502 psoriasis patients over the age of 20 years and 24,285 age- and sex-frequency-matched controls. The prevalence of hypertension was significantly higher in psoriasis patients than controls (38.8%, 29.1%, respectively, p<0.001). In a multivariate analysis, hy...

No increased cancer risk with coal tar treatment

MedWire News - Dermatology — Fri, 29 Jan 2010 00:00:00 +0100

Clinical Picture of the Week: Severe psoriasis during pregnancy

Pulse Today Clinical Updates — Thu, 28 Jan 2010 14:24:00 +0100

This woman developed severe psoriasis during pregancy. (Source: Pulse Today Clinical Updates)

Clinical Picture of the Week: Pustular psoriasis during pregnancy

Pulse Today Clinical Updates — Thu, 28 Jan 2010 14:24:00 +0100

This woman developed severe psoriasis during pregancy. (Source: Pulse Today Clinical Updates)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Prevalence of metabolic syndrome in Japanese psoriasis patients

Journal of Dermatological Science — Thu, 28 Jan 2010 14:12:54 +0100

Metabolic syndrome is a constellation of multiple risk factors including central obesity, dyslipidemia, glucose intolerance, and elevated blood pressure. The syndrome is associated with cardiovascular disease and type 2 DM , and non-alcoholic steatohepatitis (NASH) . Several reports indicate the association between psoriasis and DM, hypertension, obesity, and metabolic syndrome in Caucasian and Chinese psoriasis . Although we have shown the increased prevalence of obesity and adiposity in Japanese psoriasis , the incidence of DM, hypertension, cardiovascular disease, and the metabolic syndrome remains to be determined. (Source: Journal of Dermatological Science)

Up-regulation of serpin SCCA1 is associated with epidermal barrier disruption

Journal of Dermatological Science — Thu, 28 Jan 2010 14:12:52 +0100

Conclusion: All of our findings indicate that SCCA1 plays an important role in the induction of epidermal barrier disruption. SCCA1 may be a critical determinant of barrier function in the epidermis. (Source: Journal of Dermatological Science)

Tumor necrosis factor [alpha] blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells

Arthritis and Rheumatism — Thu, 28 Jan 2010 00:00:00 +0100

This study was undertaken to explore the mechanisms underlying TNF[alpha] blockade-induced exacerbation of skin inflammation in murine psoriasis-like skin disease.Skin inflammation was induced in BALB/c scid/scid mice after they received CD4+CD45RBhighCD25- (naive CD4) T cells from donor mice. These mice were treated with either anti-interleukin-12 (anti-IL-12)/23p40 antibody or murine TNFRII-Fc fusion protein and were examined for signs of disease, including histologic features, various cytokine levels in the serum, and cytokine or FoxP3 transcripts in the affected skin and draining lymph node (LN) cells. In a separate study, naive CD4+ T cells were differentiated into Th1 or Th17 lineages with anti-CD3/28 magnetic beads and appropriate cytokines in the presence or absence of TNF[alpha]. ...

Infliximab: Psoriasis: case report

Reactions — Wed, 27 Jan 2010 14:05:47 +0100

(Source: Reactions)

Slide show: Types of psoriasis

MayoClinic.com Full Feed — Wed, 27 Jan 2010 06:00:00 +0100

Psoriasis pictures — See pictures of types of psoriasis, including guttate psoriasis and scalp psoriasis. (Source: MayoClinic.com Full Feed)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions

Annals of the Rheumatic Diseases — Tue, 26 Jan 2010 10:24:11 +0100

Conclusions: Adalimumab was effective in patients with PsA. Lower impairment of physical function, greater pain, male sex and no systemic treatment with glucocorticoids were factors that increased the chance of achieving a good clinical response. (Source: Annals of the Rheumatic Diseases)

CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis

Arthritis Research and Therapy — Tue, 26 Jan 2010 00:00:00 +0100

Conclusions: The frequency of circulating CD14+CD16+ cells was increased in PsA compared to controls. OCP might undergo a transitional state with an intermediate expression of CD16 during osteoclastogenesis. TNFalpha blocks CD16 expression on a subset of CD14+ monocytes. CD16 has the potential to serve as an OCP marker in inflammatory arthritis. (Source: Arthritis Research and Therapy)

Topical hydrocortisone, clobetasol propionate, and calcipotriol do not increase photocarcinogenesis induced by simulated solar irradiation in hairless mice

Experimental Dermatology — Mon, 25 Jan 2010 00:00:00 +0100

Please cite this paper as: Topical hydrocortisone, clobetasol propionate, and calcipotriol do not increase photocarcinogenesis induced by simulated solar irradiation in hairless mice. Experimental Dermatology 2010.Abstract: Topical corticosteroids such as hydrocortisone-17-butyrate (HCB) and clobetasol-17-propionate (CP) and vitamin D3 derivatives such as calcipotriol (CAL) are widely used to treat psoriasis. The immunosuppressive effects of corticosteroids make their topical use a concern for skin carcinogenicity. Few studies have assessed the effect of topical corticosteroids and topical vitamin D3 derivatives on photocarcinogenesis induced by ultraviolet radiation. We investigated whether HCB, CP, or CAL can accelerate photocarcinogenesis using simulated solar radiation (SSR). HCB, CP, ...

Sue Visit 1 - A 34-year-old woman with longstanding psoriasis and onset of stiffness and foot pain (CME)

Modern Medicine — Mon, 25 Jan 2010 00:00:00 +0100

Upon completion of the activity, participants should be able to outline the cutaneous and musculoskeletal features of psoriatic arthritis; discuss the impact of psoriatic arthritis on quality of life and morbidity; identify and manage comorbidities in patients with psoriatic arthritis. (Source: Modern Medicine)

Rising psoriasis treatment costs outstrip inflation

MedWire News - Psoriasis — Sat, 23 Jan 2010 14:00:35 +0100

The cost of systemic therapies for psoriasis in the USA appears to be increasing at a faster rate than inflation, cost model findings suggest. (Source: MedWire News - Psoriasis)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Sue Visit 2 - A 34-year-old woman with longstanding psoriasis and onset of stiffness and foot pain (CME)

Modern Medicine — Sat, 23 Jan 2010 00:00:00 +0100

Rising psoriasis treatment costs outstrip inflation

MedWire News - Dermatology — Fri, 22 Jan 2010 00:00:00 +0100

The cost of systemic therapies for psoriasis in the USA appears to be increasing at a faster rate than inflation, cost model findings suggest. (Source: MedWire News - Dermatology)

Purification of Antimicrobial Peptides from Human Skin

Springer protocols feed by Immunology — Fri, 22 Jan 2010 00:00:00 +0100

Human skin is a rich source of human antimicrobial peptides. Its cellular source is the keratinocyte, which terminally differentiates in the uppermost parts of the skin, eventually forming the stratum corneum, the horny layer. The easy availability of human stratum corneum makes it possible to identify and characterize human antimicrobial peptides with a biochemical approach. Moreover, the availability of lesional scales of patients with psoriasis, an inflammatory skin disease, allows the identification of human-inducible peptide antibiotics, which are absent in healthy skin. With this strategy, the beta-defensins hBD-2 and hBD-3, RNase-7 as well as psoriasin/S100A7 have been discovered as human antimicrobial peptides and proteins. (Source: Springer protocols feed by Immunology)

Rising Costs -- the Real Heartbreak of Psoriasis (CME/CE)

MedPage Today Dermatology — Wed, 20 Jan 2010 13:13:02 +0100

Treatment costs for psoriasis have outpaced inflation, researchers said. (Source: MedPage Today Dermatology)

Modulating T cell functions does not alleviate chronic inflammatory skin lesions in K5.TGFβ1 transgenic mice

Experimental Dermatology — Wed, 20 Jan 2010 00:00:00 +0100

Please cite this paper as: Modulating T cell functions does not alleviate chronic inflammatory skin lesions in K5.TGF[beta]1 transgenic mice. Experimental Dermatology 2009.Abstract: To use mice with chronic hyperproliferative skin inflammation as psoriasis models, their thorough phenotypic and functional characterization is indispensable. Mice with keratin 5 promoter-controlled overexpression of latent human Transforming Growth Factor (TGF)[beta]1 within the basal epidermis (K5.TGF[beta]1 mice) show a psoriasiform phenotype, but the underlying pathogenic mechanisms are not entirely clear. To elucidate the contribution of T lymphocytes to the pathogenesis in K5.TGF[beta]1 mice, we used three complementary approaches: first, peripheral T cells were eradicated via systemic treatment with CD3-...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Costs of psoriasis treatment

Medicineworld.org: New Article Alert — Tue, 19 Jan 2010 14:04:47 +0100

Findings from a cost model suggest that expenses for systemic psoriasis treatment appear to be increasing at a faster rate than inflation, and newer biologically derived therapys are more expensive than traditional systemic therapies, as per a report in the recent issue of Archives of Dermatology, one of the JAMA/Archives journals........ (Source: Medicineworld.org: New Article Alert)

Cost of Psoriasis Drugs Rising Faster Than Others

MedicineNet Skin General — Tue, 19 Jan 2010 07:00:00 +0100

Title: Cost of Psoriasis Drugs Rising Faster Than OthersCategory: Health NewsCreated: 1/18/2010 4:10:00 PMLast Editorial Review: 1/19/2010 (Source: MedicineNet Skin General)

Consensus Guidelines for Psoriasis-Related Disease

Medscape Dermatology Headlines — Tue, 19 Jan 2010 05:34:23 +0100

These recommendations will help clinicians quickly review the available data to select the best therapies. Medscape Rheumatology (Source: Medscape Dermatology Headlines)

Two psoriasis drugs reduce symptoms

Health News - UPI.com — Tue, 19 Jan 2010 04:47:49 +0100

MANCHESTER, England, Jan. 18 (UPI) -- Clinical trials of two prescription drugs for psoriasis were effective in reducing symptoms of psoriasis, British researchers said. (Source: Health News - UPI.com)

Pulsed Dye Laser in the Treatment of Nail Psoriasis

Dermatologic Surgery — Tue, 19 Jan 2010 00:00:00 +0100

The treatment options for nail psoriasis have been limited, and the management of nail psoriasis has been challenging for physicians. To evaluate the effect of pulsed dye laser (PDL) in the treatment of nail psoriasis. Psoriatic nails of five patients were treated using PDL (595 nm) once monthly for 3 months. The pulse duration was 1.5 ms, the beam diameter was 7 mm, and the laser energy was 8.0 to 10.0 J/cm2. Clinical efficacy was statistically evaluated according to Nail Psoriasis Severity Index (NAPSI) score differences before and after the treatment. Statistical analysis of NAPSI scores before and after treatment showed significant difference (p (Source: Dermatologic Surgery)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Cost-effectiveness analysis of TNF-α blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system

Dermatologic Therapy — Tue, 19 Jan 2010 00:00:00 +0100

The objectives of this study was to perform a cost-effectiveness analysis of infliximab compared with other anti-tumor necrosis factor-[alpha] agents for the treatment of psoriasis in Italy. The incremental cost-effectiveness ratio per patients achieving at least 75% improvement in the psoriasis area and severity index assessed over 24- and 48[ndash]50-week periods was calculated. Efficacy data were drawn from randomized controlled trials when available or from open label studies. Considering patients achieving psoriasis area and severity index at week 24 and 48[ndash]50, infliximab was dominant (more effective and less costly) over etanercept given at 50 mg twice weekly. In contrast, infliximab was not dominant over etanercept at other dosages or over adalimumab. When considering the impa...

Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy

Dermatologic Therapy — Tue, 19 Jan 2010 00:00:00 +0100

Obesity is common in psoriatic patients, and it has been shown to be important for many aspects of the condition. In particular, low-calorie diets can improve the symptoms and response to treatment in pustular psoriasis. The present study investigates the influence of body-weight alteration on the disease's clinical manifestations in moderate to severe psoriasis patients treated with biological drugs. Finally, the influence of a caloric restriction was assessed. This observational transversal study enrolled 33 patients attending our Severe Psoriasis Outpatient Clinic, who were treated with biological drugs. Body Mass Index (BMI) was used as a diagnostic indicator of being overweight and of obesity. Waist circumference was also measured. Body weight and Psoriasis Area Severity Index (PASI) ...

Prevalence of autoantibodies in patients of psoriasis

Journal of Clinical Laboratory Analysis — Tue, 19 Jan 2010 00:00:00 +0100

This study concludes that the autoantibodies are found to be present in psoriasis patients or latent autoimmune diseases develop in psoriasis patients without any clinical symptoms. J. Clin. Lab. Anal. 24:44-48, 2010. © 2010 Wiley-Liss, Inc. (Source: Journal of Clinical Laboratory Analysis)

Rising Psoriasis Therapy Costs Far Outstrip Inflation

Modern Medicine — Tue, 19 Jan 2010 00:00:00 +0100

The price of brand-name drugs, and thus the overall cost of treating systemic psoriasis, rose steeply from 2000 to 2008, with the average 66 percent price hike far outstripping the rate of inflation over the same period, according to a study in the January issue of the Archives of Dermatology. (Source: Modern Medicine)

Rising Psoriasis Therapy Costs Far Outstrip Inflation

Modern Medicine Medical Economics — Tue, 19 Jan 2010 00:00:00 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Severe form of psoriasis ups heart disease risk

Reuters: Health — Mon, 18 Jan 2010 21:20:18 +0100

NEW YORK (Reuters Health) - People with severe forms of the inflammatory skin disease psoriasis are more likely to die of heart-related causes and stroke than those without the condition, new research shows. (Source: Reuters: Health)

Severe Form of Psoriasis Ups Heart Disease Risk

MedlinePlus Health News — Mon, 18 Jan 2010 21:20:18 +0100

People with severe forms of the inflammatory skin disease psoriasis are more likely to die of heart-related causes and stroke than those without the condition, new research shows. Source: Reuters Health Related MedlinePlus Topics: Heart Diseases, Psoriasis, Stroke (Source: MedlinePlus Health News)

Recent Trends in Systemic Psoriasis Treatment Costs [Study]

Archives of Dermatology — Mon, 18 Jan 2010 20:51:27 +0100

Conclusions Despite the higher monitoring costs associated with traditional systemic therapies, annual costs of biologics exceed those of other available therapies. Current trends demonstrate that systemic psoriasis therapy costs are increasing at a much higher rate compared with general inflation. (Source: Archives of Dermatology)

Psoriasis drugs put to the test

ScienceDaily Headlines — Mon, 18 Jan 2010 15:53:06 +0100

Effect of new Pulian Ointment (新普连膏) in treating psoriasis of blood-heat syndrome: A randomized controlled trial

Chinese Journal of Integrative Medicine — Mon, 18 Jan 2010 07:38:29 +0100

Conclusion NPLO is a Chinese remedy for the external treatment of psoriasis of the blood-heat syndrome with a reliable therapeutic efficacy and good safety. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s11655-009-0409-0Authors Ning Zhou, China-Japan Friendship Hospital Department of Dermatology Beijing 100029 ChinaYan-ping Bai, China-Japan Friendship Hospital Department of Dermatology Beijing 100029 ChinaXiao-hong Man, China-Japan Friendship Hospital Department of Dermatology Beijing 100029 ChinaYun-bi Zhang, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Department of Dermatology Beijing 100700 ChinaYu-hong Kong, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine Department of Dermatology Beijing 100076...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Costs of psoriasis treatments outpace inflation

EurekAlert! - Medicine and Health — Mon, 18 Jan 2010 05:00:00 +0100

(JAMA and Archives Journals) Findings from a cost model suggest that expenses for systemic psoriasis therapy appear to be increasing at a faster rate than inflation, and newer biologically derived treatments are more expensive than traditional systemic therapies, according to a report in the January issue of Archives of Dermatology, one of the JAMA/Archives journals. (Source: EurekAlert! - Medicine and Health)

Expression of cyclin D1 and p16 in psoriasis before and after phototherapy

Clinical And Experimental Dermatology — Mon, 18 Jan 2010 00:00:00 +0100

Conclusion. Cyclin D1 upregulation and p16 downregulation may play a role in the pathogenesis of psoriasis. Normalization of the levels of both parameters may be a mechanism by which phototherapy induces remission in psoriasis. (Source: Clinical And Experimental Dermatology)

Iatrogenic adrenal insufficiency associated with calcipotriol–betamethasone topical combination in psoriasis

Clinical And Experimental Dermatology — Mon, 18 Jan 2010 00:00:00 +0100

(Source: Clinical And Experimental Dermatology)

Review: Managing co-morbid disease in patients with psoriasis

NeLM - Dermatology — Mon, 18 Jan 2010 00:00:00 +0100

Source: BMJ Area: News In this review article, the authors look at co-morbid diseases in patients with psoriasis, focusing on their relation to psoriasis and how their presence influences treatment decisions and management for these patients. The following issues are discussed: . Which co-morbidities are now recognised as important in psoriasis? . How is psoriasis related to its co-morbidities? . How can co-morbidities be diagnosed early? . How might co-morbidities influence treatment decisions? . What's new in psoriasis management? . What can we learn from psoriasis as a model of an immune mediated inflammatory disorder? The following tips are given for non-specialists: . Only severe psoriasis confers a substa...

Ustekinumab shows superior efficacy in moderate-to-severe psoriasis

MedWire News - Dermatology — Sat, 16 Jan 2010 14:00:44 +0100

Ustekinumab appears to more effective than etanercept for the treatment of moderate-to-severe psoriasis, with a similar safety profile, say researchers. (Source: MedWire News - Dermatology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Ustekinumab shows superior efficacy in moderate-to-severe psoriasis

MedWire News - Psoriasis — Sat, 16 Jan 2010 14:00:44 +0100

Ustekinumab appears to more effective than etanercept for the treatment of moderate-to-severe psoriasis, with a similar safety profile, say researchers. (Source: MedWire News - Psoriasis)

New Biologic Bests Older One in Psoriasis (CME/CE)

MedPage Today Dermatology — Sat, 16 Jan 2010 12:43:02 +0100

The dual cytokine inhibitor ustekinumab (Stelara) outperformed etanercept (Enbrel) for treatment of psoriasis, investigators in a multicenter clinical trial reported. (Source: MedPage Today Dermatology)

Managing comorbid disease in patients with psoriasis

BMJ Online First — Fri, 15 Jan 2010 11:53:47 +0100

(Source: BMJ Online First)

STELARA(TM) Shows Greater Efficacy Than Etanercept For Treatment Of Moderate To Severe Plaque Psoriasis

Health News from Medical News Today — Fri, 15 Jan 2010 09:00:00 +0100

Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque psoriasis appear in The New England Journal of Medicine. The results showed a significantly higher clinical response with both doses of STELARA than with etanercept over a 12-week period. The first-of-its-kind head-to-head study comparing two biologic agents for plaque psoriasis also shows the efficacy of STELARA among patients in the study who failed to respond to etanercept... (Source: Health News from Medical News Today)

STELARA(TM) Shows Greater Efficacy Than Etanercept For Treatment Of Moderate To Severe Plaque Psoriasis

Immune System / Vaccines News From Medical News Today — Fri, 15 Jan 2010 09:00:00 +0100

Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the treatment of moderate to severe plaque psoriasis appear in The New England Journal of Medicine. The results showed a significantly higher clinical response with both doses of STELARA than with etanercept over a 12-week period... (Source: Immune System / Vaccines News From Medical News Today)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Putting Psoriasis Drugs To The Test

Health News from Medical News Today — Fri, 15 Jan 2010 08:00:00 +0100

Clinical trials to test the effectiveness of two prescription drugs for the debilitating skin condition psoriasis have revealed significant differences that should help inform physicians treating patients with the condition. Researchers at The University of Manchester compared the drugs etanercept and ustekinumab - relatively new biological therapies that have proved effective in the management of moderate to severe psoriasis. Little research has been done to test the benefit-risk profiles of these new biological agents or compare their relative effectiveness... (Source: Health News from Medical News Today)

Reply to Alberto Giannetti, MD, PhD commentary regarding the European S3-Guidelines on the systemic treatment of Psoriasis

Journal of the European Academy of Dermatology and Venereology — Fri, 15 Jan 2010 00:00:00 +0100

(Source: Journal of the European Academy of Dermatology and Venereology)

Model-based approaches for time-dependent dose finding with repeated binary data

Statistics in Medicine — Fri, 15 Jan 2010 00:00:00 +0100

The goal of a clinical Phase II dose finding study is to describe the dose response relationship and to find a target dose (TD) or dose range that ensures a certain efficacy. In many applications, however, it is useful to consider combinations of dose and time under treatment instead of the dose only. The estimation of a minimum effective dose as a function of time allows, e.g. for a decision on an optimal initial treatment duration, if this initial treatment is followed by a maintenance therapy or aftercare which is supposed to start when a certain response rate is achieved. Bretz et al. (Biometrics 2005; 61:738-748) proposed a methodology that combines formal hypothesis testing for dose response with flexible modeling of the dose response relationship and estimating a target dose. In thi...

Stelara Shows Greater Efficacy than Etanercept for Treatment Of Moderate-To-Severe Plaque Psoriasis

Drugs.com - Clinical Trials — Thu, 14 Jan 2010 15:35:32 +0100

Study Also Evaluated Etanercept Non-responders Switched to STELARA® Toronto, ON, (January 14, 2010) —Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA® (ustekinumab) with Enbrel*... (Source: Drugs.com - Clinical Trials)

Health News of the Day

Clinical Cases and Images — Thu, 14 Jan 2010 14:30:00 +0100

is a daily summary made from the selected links I post on Twitter. It is in a bullet points format with links to the original sources which include 350 RSS feeds that produce about 2,500 items per day: Human Male: Still A Work In Progress - Y chromosome is changing far more rapidly than the rest of the genome. Y chromosome is in "an evolutionary freefall", looks like a house that's constantly being remodeled http://bit.ly/7LV50B Primary care doctors could see a 1.1% Medicare pay increase this year but cost of practicing medicine will rise 2.5% http://bit.ly/6nmApE Oncologists Using Twitter to Advance Cancer Knowledge - Oncology Times, 2010 http://bit.ly/4vpcn8 - Applicable to most physicians. At Hospitals in China, Caesarean Rate Nears 50%. Commentary called the study results “surp...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

STELARA®* Shows Greater Efficacy than Etanercept for Treatment Of Moderate-To-Severe Plaque Psoriasis(Jan 14, 2010)

Johnson and Johnson — Thu, 14 Jan 2010 14:00:57 +0100

Toronto, ON, (January 14, 2010) —Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA® (ustekinumab) with Enbrel* (etanercept) in the treatment of moderate to severe plaque psoriasis showed a significantly higher clinical response with both doses of STELARA® than etanercept over a 12-week period. The first-of-its-kind head-to-head study comparing two biologic agents for plaque psoriasis also shows the efficacy of STELARA® among patients in the study who failed to respond to etanercept. The international study included 18 Canadian sites. Findings from this study have been published in the January issue of The New England Journal of Medicine (Source: Johnson and Johnson)

STELARA Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine

Drugs.com - Clinical Trials — Thu, 14 Jan 2010 13:30:36 +0100

Study Also Evaluated Etanercept Non-responders Switched to STELARA HORSHAM, Pa., Jan. 14 /PRNewswire/ -- Findings from an international, Phase 3 clinical study comparing the efficacy and safety of STELARA(TM) (ustekinumab) with etanercept... (Source: Drugs.com - Clinical Trials)

STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis

HSMN NewsFeed — Thu, 14 Jan 2010 11:24:31 +0100

Results From First Phase III Comparator Study of Biologic Agents in Psoriasis Published Today in New England Journal of Medicine HIGH WYCOMBE, England, January 14 (HSMN NewsFeed) -- Findings from a new Phase III study comparing the efficacy and safety... Biopharmaceuticals, DermatologyJanssen-Cilag, Johnson & Johnson, STELARA, ustekinumab, psoriasis (Source: HSMN NewsFeed)

Stelara Beats Enbrel in Psoriasis Study

MedicineNet Cancer General — Thu, 14 Jan 2010 07:00:00 +0100

Title: Stelara Beats Enbrel in Psoriasis StudyCategory: Health NewsCreated: 1/14/2010 10:10:00 AMLast Editorial Review: 1/14/2010 10:10:53 AM (Source: MedicineNet Cancer General)

Stelara Beats Enbrel in Psoriasis Study

MedicineNet Skin General — Thu, 14 Jan 2010 07:00:00 +0100

Title: Stelara Beats Enbrel in Psoriasis StudyCategory: Health NewsCreated: 1/14/2010 10:10:00 AMLast Editorial Review: 1/14/2010 10:10:53 AM (Source: MedicineNet Skin General)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Newer Drug More Effective in Psoriasis Treatment

MedicineNet Skin General — Thu, 14 Jan 2010 07:00:00 +0100

Title: Newer Drug More Effective in Psoriasis TreatmentCategory: Health NewsCreated: 1/13/2010 4:10:00 PMLast Editorial Review: 1/14/2010 (Source: MedicineNet Skin General)

Newer Drug More Effective in Psoriasis Treatment

MedicineNet Diabetes General — Thu, 14 Jan 2010 07:00:00 +0100

Title: Newer Drug More Effective in Psoriasis TreatmentCategory: Health NewsCreated: 1/13/2010 4:10:00 PMLast Editorial Review: 1/14/2010 (Source: MedicineNet Diabetes General)

Stelara Beats Enbrel in Psoriasis Study

MedicineNet Senior Health General — Thu, 14 Jan 2010 07:00:00 +0100

Title: Stelara Beats Enbrel in Psoriasis StudyCategory: Health NewsCreated: 1/14/2010 10:10:00 AMLast Editorial Review: 1/14/2010 10:10:53 AM (Source: MedicineNet Senior Health General)

Newer Drug More Effective in Psoriasis Treatment

MedicineNet Senior Health General — Thu, 14 Jan 2010 07:00:00 +0100

Title: Newer Drug More Effective in Psoriasis TreatmentCategory: Health NewsCreated: 1/13/2010 4:10:00 PMLast Editorial Review: 1/14/2010 (Source: MedicineNet Senior Health General)

Stelara Beats Enbrel in Psoriasis Study

eMedicineHealth.com — Thu, 14 Jan 2010 07:00:00 +0100

(Source: eMedicineHealth.com)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Newer Drug More Effective in Psoriasis Treatment

MedicineNet Migraine General — Thu, 14 Jan 2010 07:00:00 +0100

Title: Newer Drug More Effective in Psoriasis TreatmentCategory: Health NewsCreated: 1/13/2010 4:10:00 PMLast Editorial Review: 1/14/2010 (Source: MedicineNet Migraine General)

Stelara Beats Enbrel in Psoriasis Study

MedicineNet Depression General — Thu, 14 Jan 2010 07:00:00 +0100

Title: Stelara Beats Enbrel in Psoriasis StudyCategory: Health NewsCreated: 1/14/2010 10:10:00 AMLast Editorial Review: 1/14/2010 10:10:53 AM (Source: MedicineNet Depression General)

Newer Drug More Effective in Psoriasis Treatment

MedicineNet Depression General — Thu, 14 Jan 2010 07:00:00 +0100

Title: Newer Drug More Effective in Psoriasis TreatmentCategory: Health NewsCreated: 1/13/2010 4:10:00 PMLast Editorial Review: 1/14/2010 (Source: MedicineNet Depression General)

Psoriasis Drugs Tested

Disabled World — Thu, 14 Jan 2010 03:05:48 +0100

RCT: Ustekinumab vs. etanercept in psoriasis

NeLM - Dermatology — Thu, 14 Jan 2010 00:00:00 +0100

Source: N Engl J Med Area: News A controlled trial found that ustekinumab gave better outcomes in moderate to severe psoriasis than etanercept. The study involved patients with moderate to severe psoriasis, who were randomised to receive either ustekinumab (blocks the actions of the cytokines interleukin-12 and interleukin-23), 45 mg or 90 mg for two doses, four weeks apart, or etanercept 50mg twice weekly for 12 weeks. A double-dummy technique was used to preserve blinding. Primary outcome was the proportion of patients with at least 75% improvement in the psoriasis area-and-severity index (PASI) at week 12. Of 1175 patients screened, 903 were randomised to treatment (ustekinumab 45 mg n=209, 90mg n=347, etanercept n=347). At twelve weeks, more patients in the ustek...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Psoriasis: impact and management of moderate to severe disease.

British Journal of Nursing — Thu, 14 Jan 2010 00:00:00 +0100

This article summarizes these treatments and the nursing care required for the patient in severe flare; it discusses the considerations the nurse should have in enabling a patient to self-manage their condition, offering support that is practical and psychological, with health education often including family and carers. PMID: 20081706 [PubMed - as supplied by publisher] (Source: British Journal of Nursing)

Ustekinumab Superior to Etanercept in Treating Moderate to Severe Psoriasis in Short-Term Study

Medscape Dermatology Headlines — Wed, 13 Jan 2010 22:32:43 +0100

Ustekinumab Superior to Etanercept in Treating Moderate to Severe Psoriasis Medscape Medical News (Source: Medscape Dermatology Headlines)

Stelara Beats Enbrel in Psoriasis Study

WebMD Health — Wed, 13 Jan 2010 22:04:47 +0100

A recently approved drug, Stelara, is more effective than a more established drug, Enbrel, in treating moderate to severe psoriasis, according to a new study. (Source: WebMD Health)

Newer Drug More Effective in Psoriasis Treatment

MedlinePlus Health News — Wed, 13 Jan 2010 22:00:00 +0100

Stelara tops Enbrel in head-to-head comparison and requires fewer injections, researchers say Source: HealthDay Related MedlinePlus Topics: Medicines, Psoriasis (Source: MedlinePlus Health News)

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

New England Journal of Medicine — Wed, 13 Jan 2010 00:00:00 +0100

In this 12-week randomized trial comparing two biologic agents known to be effective for psoriasis, ustekinumab (an interleukin-12 and interleukin-23 blocker) was more effective than etanercept (an inhibitor of tumor necrosis factor {alpha}). Adverse events associated with the two treatments were similar, but the trial was not large enough and follow-up was not long enough to assess uncommon adverse events. (Source: New England Journal of Medicine)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Generalized Ostraceous Psoriasis

New England Journal of Medicine — Wed, 13 Jan 2010 00:00:00 +0100

A 47-year-old woman presented to our hospital with a 2-week history of widespread, painful lesions on her trunk and limbs (Panels A and B). Her medical history included hypercholesterolemia, diabetes, ... (Source: New England Journal of Medicine)

CME: Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

New England Journal of Medicine — Wed, 13 Jan 2010 00:00:00 +0100

(No abstract is available for this citation) (Source: New England Journal of Medicine)

Ustekinumab Deemed Superior to Etanercept for Psoriasis

Modern Medicine — Wed, 13 Jan 2010 00:00:00 +0100

In patients with moderate-to-severe psoriasis, treatment with ustekinumab at a dose of 45 or 90 mg is more effective than treatment with high-dose etanercept, according to a study in the Jan. 14 New England Journal of Medicine. (Source: Modern Medicine)

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

Clinical Rheumatology — Tue, 12 Jan 2010 06:44:48 +0100

Abstract The aim of this study is to compare effectiveness and safety of Infliximab (INF), Etanercept (ETN), and Adalimumab (ADA) in patients with psoriatic arthritis (PsA) with inadequate response to a previous disease-modifying antirheumatic drug (DMARD). One hundred consecutive PsA patients with inadequate response to a previous DMARD entered this study. Clinical and laboratory assessment at baseline (T0) and 12 (T12) months were performed and included physical examination, vital signs, global Psoriasis Area and Severity Index (PASI; extension of psoriasis), tender joints count (TJC), swollen joint count, health assessment questionnaire (HAQ; questionnaire for measuring disability), and monitoring of adverse events (AEs). After enrolment, all patients were randomly give...

Role of AUF1 in splenic size and follicular B cell maintenance

BMC Immunology — Mon, 11 Jan 2010 00:00:00 +0100

Conclusions: Functionally, AUF1-deficient mice mount an attenuated response to T cell-independent (TI) antigen. These results indicate that AUF1 is important in the maintenance of splenic FO B cells and adequate humoral immune responses. (Source: BMC Immunology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Well being, psychopathology and coping strategies in psoriasis compared with atopic dermatitis: a controlled study

Journal of the European Academy of Dermatology and Venereology — Mon, 11 Jan 2010 00:00:00 +0100

Conclusions We propose two explanations, derived from the psychological and the psycho-neuro-immunological domains. First, greater mental distress in psoriasis is because of the greater stigma it bears compared with AD. Alternatively, we hypothesize that the psoriatic inflammatory process may possibly have a direct central nervous system effect. (Source: Journal of the European Academy of Dermatology and Venereology)

Commentary on the European S3-Guidelines on the systemic treatment of Psoriasis

Journal of the European Academy of Dermatology and Venereology — Mon, 11 Jan 2010 00:00:00 +0100

(Source: Journal of the European Academy of Dermatology and Venereology)

Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument for Sweden.

Scandinavian Journal of Rheumatology — Mon, 11 Jan 2010 00:00:00 +0100

Conclusions: This study provides evidence that the adapted PsAQoL can be used for clinical studies in Swedish patients. The instrument provides valuable information on the long-term effects of PsA on QoL. PMID: 20063984 [PubMed - as supplied by publisher] (Source: Scandinavian Journal of Rheumatology)

Blockage of JNK pathway enhances arsenic trioxide-induced apoptosis in human keratinocytes.

Toxicology and Applied Pharmacology — Mon, 11 Jan 2010 00:00:00 +0100

Authors: Huang HS, Liu ZM, Hong DY Arsenic is well-known as a carcinogen predisposing humans to some severe diseases and also as an effective medicine for treating acute promyelocytic leukemia, syphilis, and psoriasis. Multiple active mechanisms, including cell cycle arrest and apoptosis, have been proposed in therapy; however, the opposing effects of arsenic remain controversial. Our previous study found that arsenic trioxide (ATO)-induced activation of p21(WAF1/CIP1) (p21) led to A431 cell death through the antagonistic effects of the signaling of ERK1/2 and JNK1. In the current study, the inhibitory effects of JNK1 on ATO-induced p21 expression were explored. Over-expression of JNK1 in A431cells could inhibit p21 expression, which was associated with HDAC1 and TGIF. Using the GST pu...

CRP proposed as marker for psoriasis severity

MedWire News - Dermatology — Sat, 09 Jan 2010 14:01:53 +0100

C-reactive protein appears to be a useful marker of psoriasis severity, say researchers who believe it could be used to monitor the disease and its treatment. (Source: MedWire News - Dermatology)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

CRP proposed as marker for psoriasis severity

MedWire News - Psoriasis — Sat, 09 Jan 2010 14:01:53 +0100

C-reactive protein appears to be a useful marker of psoriasis severity, say researchers who believe it could be used to monitor the disease and its treatment. (Source: MedWire News - Psoriasis)

Clinical comparison of psoriasis in Korean adults and children: correlation with serum anti-streptolysin O titers

Archives of Dermatological Research — Fri, 08 Jan 2010 21:37:27 +0100

In conclusion, if the children with psoriasis show increased ASO titer, the physician should pay attention to the worsening of the psoriasis. Furthermore, early treatment of streptococcal infections might be beneficial in childhood psoriasis. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s00403-009-1025-8Authors Sue Kyung Kim, Ajou University School of Medicine Department of Dermatology 5 Wonchon-Dong, Yeongtong-Gu Suwon 443-721 South KoreaHee Young Kang, Ajou University School of Medicine Department of Dermatology 5 Wonchon-Dong, Yeongtong-Gu Suwon 443-721 South KoreaYou Chan Kim, Ajou University School of Medicine Department of Dermatology 5 Wonchon-Dong, Yeongtong-Gu Suwon 443-721 South KoreaEun-So Lee, Ajou University School of Medicine Department of Dermat...

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT

Arthritis Research and Therapy — Fri, 08 Jan 2010 00:00:00 +0100

Conclusion: No significant differences in the overall incidence of malignancies in patients exposed or unexposed to anti-TNFalpha or anakinra treatment were found. The same applied to the risk of recurrent malignancies. However, in particular this last finding needs further validation in larger data sets. (Source: Arthritis Research and Therapy)

VBL Therapeutics Initiates Phase 2 Clinical Trial Of VB-201 In Patients With Psoriasis

Health News from Medical News Today — Thu, 07 Jan 2010 18:00:00 +0100

VBL Therapeutics announced the initiation of a Phase 2 efficacy and safety study evaluating lead compound VB-201 for the treatment of patients with psoriasis. VB-201 is poised to be a first-in-class, orally-administered immune response modifier expected to reduce inflammation in a broad range of conditions such as psoriasis. The Phase 2 double-blind, randomized, dose-ranging, placebo-controlled study will enroll approximately 180 patients with moderate to severe psoriasis. Patients will receive VB-201 or placebo once-daily for 12 weeks... (Source: Health News from Medical News Today)

VBL Therapeutics Initiates Phase 2 Clinical Trial Of VB-201 In Patients With Psoriasis

Dermatology News From Medical News Today — Thu, 07 Jan 2010 18:00:00 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

InNexus Biotechnology Develops New Psoriasis Product Based On Its Skin Permeating Antibody Technology

Health News from Medical News Today — Thu, 07 Jan 2010 12:00:00 +0100

InNexus Biotechnology Inc. (TSX.V: IXS) , a drug development company commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL™) technology, announced the development of a new psoriasis product based on its proprietary dermal permeating Transmab™ technology. Scientists at InNexus have designed and produced by recombinant technology, a novel antibody product directed at treatment of psoriasis, an autoimmune skin disease... (Source: Health News from Medical News Today)

InNexus Biotechnology Develops New Psoriasis Product Based On Its Skin Permeating Antibody Technology

Dermatology News From Medical News Today — Thu, 07 Jan 2010 12:00:00 +0100

Organising pneumonia associated with fumaric acid ester treatment for psoriasis

The Clinical Respiratory Journal — Thu, 07 Jan 2010 00:00:00 +0100

Conclusions: Therapy with oral prednisolone (40 mg/day) resulted in a rapid clinical and radiological improvement. An association of FAE and OP has not previously been reported. Please cite this paper as: Deegan AP, Kirby B, Rogers S, Crotty TB and McDonnell TJ. Organising pneumonia associated with fumaric acid ester treatment for psoriasis. The Clinical Respiratory Journal 2009; DOI:10.1111/j.1752-699X.2009.00180.x. (Source: The Clinical Respiratory Journal)

Levia® For Personal Targeted Phototherapy™ Treatment Of Psoriasis Receives FDA 510 (k) Clearance

Medical Design Online News — Wed, 06 Jan 2010 04:12:27 +0100

Lerner Medical Devices, Inc. announced today that Levia®, a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psoriasis and certain other skin conditions such as vitiligo (Source: Medical Design Online News)

A comparison of three times vs. five times weekly narrowband ultraviolet B phototherapy for the treatment of chronic plaque psoriasis

Photodermatology, Photoimmunology and Photomedicine — Wed, 06 Jan 2010 00:00:00 +0100

Narrowband ultraviolet B (NB-UVB) phototherapy is an effective treatment for psoriasis. To compare the effects of three and five times weekly NB-UVB phototherapy in the treatment of chronic plaque psoriasis. Sixty-five patients with chronic plaque psoriasis were allocated to receive three or five times weekly NB-UVB, starting at low dose. Among the patients who completed the study, clearance was achieved in 18 out of 23 patients (78%) in the three times weekly group and in 15 out of 22 patients (68%) in the five times weekly group. The difference was not statistically significant (P=0.44). No statistically significant differences were found between the two groups in the number of treatments (P=0.95), cumulative UVB dose (P=0.51), and rate of side-effects. Length of the treatment period was...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Tumor necrosis factor-α-converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients

Photodermatology, Photoimmunology and Photomedicine — Wed, 06 Jan 2010 00:00:00 +0100

The aim of the study was to analyze the relationship between smoking and the treatment with narrowband ultraviolet B (NB-UVB) in psoriasis patients and to examine the role of the soluble tumor necrosis factor-[alpha] receptor type one (sTNF-R1) in plasma and that of TNF-[alpha]-converting enzyme (TACE) released from peripheral blood mononuclear cells (PBMC) in this relationship. The study has been conducted among 45 inpatients with plaque-type psoriasis vulgaris and 36 inpatients with other chronic inflammatory skin disorders from similar social background (controls). Taking into account the number of cigarettes smoked daily and the duration of smoking, subjects were classified as mild, moderate and heavy smokers. The severity of psoriasis was assessed using psoriasis area and severity ind...

Levia(R) for Personal Targeted Phototherapy(TM) Treatment of Psoriasis Receives FDA 510(k) Clearance

HSMN NewsFeed — Tue, 05 Jan 2010 17:20:44 +0100

LOS ANGELES, CA - (HSMN NewsFeed) - Lerner Medical Devices, Inc. announced today that Levia(R), a novel, in-home, ultraviolet B (UVB) phototherapy device, has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for treatment of psor... Devices, Dermatology, FDALerner Medical Devices, Levia, phototherapy, psoriasis (Source: HSMN NewsFeed)

Psoriasis may be a systemic disease

Health News - UPI.com — Mon, 04 Jan 2010 23:42:56 +0100

ROCHESTER, N.Y., Jan. 4 (UPI) -- Psoriasis, a disease that causes red, raised patches of skin, is seen as a systemic disease linked to arthritis and heart disease, a U.S. newsletter says. (Source: Health News - UPI.com)

Sonozaki syndrome: case report and review of literature

Rheumatology International — Mon, 04 Jan 2010 18:15:53 +0100

Abstract Sonozaki syndrome—pustulotic arthro-osteitis (PAO) is a relatively rare, chronic illness. This disease belongs to the group of psoriatic arthritis (psoriasis arthropatica, artropatia psoriatica) which in turn belongs to the group of seronegative arthritis. Sonozaki syndrome includes palmoplantar pustulosis, PPP as well as arthro-osteitis. Clinically, symmetrically localised pustulae are observed on feet and hands. Effected joints are painful, swollen with a visible inflammation. Here, we describe a case of a woman aged 55 with a diagnosis of Sonozaki syndrome and hyperthyroidism. At the moment of admission multiple changes in the form of pustulae were observed on hands and soles, filled with pus and blood of the erythemal basis. Oral and genital mucosa were free...

Psoriasis: Effects don’t always stop with the skin

ScienceDaily Headlines — Mon, 04 Jan 2010 10:00:00 +0100

Psoriasis, a chronic disease that causes red, raised patches of skin, is increasingly seen as a systemic disease with links to arthritis and cardiovascular disease. (Source: ScienceDaily Headlines)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Psychosocial aspects of coping with tinnitus and psoriasis patients. A comparative study of suicidal tendencies, anxiety and depression. - Schaaf H, Eipp C, Deubner R, Hesse G, Vasa R, Gieler U.

SafetyLit: All (Unduplicated) — Sun, 03 Jan 2010 15:15:30 +0100

BACKGROUND: Treatment of tinnitus is primarily the task of ENT specialists, while treatment of the psychiatric diseases lies in the hand of psychotherapists. Different from mostly very apparent dermatological diseases, the severity level of tinnitus can of... (Source: SafetyLit: All (Unduplicated))

Genomic differences identified in common skin diseases may lead to better treatments

ScienceDaily Headlines — Sat, 02 Jan 2010 10:00:00 +0100

Scientists have drilled down on the molecular nitty-gritty that distinguishes the two most common forms of inflammatory skin disease, atopic eczema and psoriasis. The researchers say that the ability to distinguish between the disorders' genetic and immunological signatures opens the door for more narrowly targeted therapies sorely needed by the millions of people afflicted worldwide. (Source: ScienceDaily Headlines)

Smoking and alcohol intake linked to severe psoriasis

MedWire News - Psoriasis — Fri, 01 Jan 2010 13:59:08 +0100

Smoking and alcohol intake are independently associated with severe forms of psoriasis, confirm researchers (Source: MedWire News - Psoriasis)

Smoking and alcohol intake linked to severe psoriasis

MedWire News - Dermatology — Fri, 01 Jan 2010 00:00:00 +0100

Smoking and alcohol intake are independently associated with severe forms of psoriasis, confirm researchers (Source: MedWire News - Dermatology)

Natural killer cells in atopic and autoimmune diseases of the skin

Journal of Allergy and Clinical Immunology — Fri, 01 Jan 2010 00:00:00 +0100

Natural killer (NK) cells are best known for their ability to recognize and kill tumor cells and virally infected cells and for their ability to produce large amounts of some cytokines, such as IFN-γ. Recent research has substantially expanded our view on the function of NK cells in the immune system in health and disease. In addition to the better-studied functions in cancer and autoimmunity, contributions from NK cells to allergies and various skin diseases have emerged. We briefly recount the traditional NK cell functions before focusing on their roles in atopic dermatitis, psoriasis, alopecia areata, and pemphigus vulgaris. Although this field is still developing, strong data are available that indicate NK cell involvement. In patients with allergic diseases, the production of TH2 cyt...

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Vaccinia virus–specific molecular signature in atopic dermatitis skin

Journal of Allergy and Clinical Immunology — Fri, 01 Jan 2010 00:00:00 +0100

Conclusion: This study identified groups of innate immunity genes that are associated with the aberrant response of AD skin to VV and represent potential targets for EV pathogenesis. (Source: Journal of Allergy and Clinical Immunology)

Predictive testing of the melanocortin 1 receptor for skin cancer and photoaging.

Skin Therapy Letter — Fri, 01 Jan 2010 00:00:00 +0100

Authors: Lynde CW, Sapra S Genetic predisposition to melanoma and nonmelanoma skin cancer extends far beyond the Fitzpatrick phenotype classification scheme. Specific alleles of the gene that codes for the malnocortin 1 receptor are predictive of skin cancer risk independent of skin type and hair color. The ability to identify high risk patients independent of the red hair phenotype may help to modify routine sun and skin monitoring behaviors. In addition, as this increased skin cancer risk is likely due to impaired UVA and UVB defence mechanisms, consideration of genetic predisposition may also be appropriate for patients undergoing psoralen + UVA (PUVA) or UVB treatments for various cutaneous disorders, such as psoriasis, eczema, and vitiligo. Testing aimed at improving prognosticati...

Infliximab Found to Clear Nail Psoriasis

Rheumatology News — Fri, 01 Jan 2010 00:00:00 +0100

BERLIN — Patients with nail psoriasis have been found to respond to infliximab in parallel with cutaneous improvement, according to the results of a new post hoc analysis of a phase III study. (Source: Rheumatology News)

Discontinue Methotrexate at Week 12 in Poor Responders

Rheumatology News — Fri, 01 Jan 2010 00:00:00 +0100

Major Finding: Don't extend methotrexate therapy past 3 months in nonresponders with psoriasis. (Source: Rheumatology News)

Ustekinumab Aids Sexual Function in Psoriasis

Clinical Psychiatry News — Fri, 01 Jan 2010 00:00:00 +0100

BERLIN — Impaired sexual function is extremely common in the setting of moderate to severe psoriasis, and ustekinumab therapy reduces these problems by 10-fold. That's a key quality-of-life finding from the ongoing randomized double-blind phase III PHOENIX-1 and −2 clinical trials of this human monoclonal antibody directed against the proinflammatory cytokines interkeukin-12 and −23, Dr. Lyn Guenther cported at the annual congress of the European Academy of Dermatology and Venereology. (Source: Clinical Psychiatry News)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Unusual presentation of tuberculosis in an infliximab-treated patient – which is the correct TB screening before starting a biologic?

Dermatologic Therapy — Fri, 01 Jan 2010 00:00:00 +0100

We report the case of a psoriatic patient, who, despite a negative screening for infection by M. tuberculosis including both tuberculin skin test (TST) and chest X-ray, developed after 4 months of infliximab treatment, a severe pulmonary, lymphnodal and intestinal tuberculosis during infliximab treatment. (Source: Dermatologic Therapy)

[Narrow-band UVB therapy in psoriasis vulgaris: Good practice guideline and recommendations of the French Society of Photodermatology.]

Annales de Dermatologie et de Cenereologie — Fri, 01 Jan 2010 00:00:00 +0100

CONCLUSION: Narrow-spectrum UVB phototherapy offers a good alternative to PUVA therapy since concomitant psoralen is not required, but there are few immediate adverse effects, there is less risk of drug-induced photosensitisation, and there is no need for skin or ocular photoprotection after sessions. We recommend this approach as the first-line phototherapy (level of proof: A) in children and adolescents, and in adults with extensive moderate psoriasis involving small superficial plaques. It may also be used in pregnant or breastfeeding women and in patients with renal or hepatic insufficiency. In addition, it is preferable for HIV-positive subjects (level of proof: C). However, PUVA therapy is preferable as first-line treatment in extensive severe psoriasis involving large thick plaques ...

Quinacrine in the treatment of cutaneous lupus erythematosus: Practical aspects and a case series.

Actas Dermo-Sifiliograficas — Fri, 01 Jan 2010 00:00:00 +0100

We report 8 cases of patients with cutaneous lupus who received treatment with quinacrine in monotherapy or in combination with others antimalarials. Lesions resolved in 5 patients and improved in 3. Therapy had to be withdrawn in 1 patient due to an exacerbation of his psoriasis. PMID: 20109393 [PubMed - as supplied by publisher] (Source: Actas Dermo-Sifiliograficas)

Long-term safety and efficacy of etanercept in the treatment of psoriasis.

Actas Dermo-Sifiliograficas — Fri, 01 Jan 2010 00:00:00 +0100

CONCLUSION: We present our clinical experience with long-term etanercept treatment in patients with moderate to severe psoriasis, with and without associated joint involvement. The efficacy and safety profiles were found to be favorable. PMID: 20109392 [PubMed - as supplied by publisher] (Source: Actas Dermo-Sifiliograficas)

Acquired dermal melanocytosis of the hand at the site of treated psoriasis.

Dermatol Online J — Thu, 31 Dec 2009 16:04:02 +0100

We report a case of acquired dermal melanocytosis occurring in a 42-year-old Hispanic man with psoriasis treated with infliximab for 9 months. The patient presented with an isolated pigmented patch on his left dorsal hand. Histopathologic examination of the skin revealed numerous dendritic, heavily pigmented melanocytes in the papillary and upper reticular dermis. We review the literature and discuss the pathogenesis of acquired dermal melanocytosis. PMID: 20040252 [PubMed - in process] (Source: Dermatol Online J)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Psoriasis: Effects Don't Always Stop With The Skin

Health News from Medical News Today — Thu, 31 Dec 2009 09:00:00 +0100

Psoriasis, a chronic disease that causes red, raised patches of skin, is increasingly seen as a systemic disease with links to arthritis and cardiovascular disease. The December issue of Mayo Clinic Women's HealthSource provides an overview of this sometimes embarrassing condition, what's known about it and how it's treated. Highlights of the overview include: -- Symptoms: Patches of thick, red skin covered with silvery, flaky scales commonly appear on the elbows and knees, but can appear anywhere on the body. They result from skin cells on overdrive, reproducing much faster than normal... (Source: Health News from Medical News Today)

Psoriasis: Effects Don't Always Stop With The Skin

Immune System / Vaccines News From Medical News Today — Thu, 31 Dec 2009 09:00:00 +0100

Placebo Effect Helps Some Psoriasis Patients

MedicineNet Skin General — Thu, 31 Dec 2009 07:00:00 +0100

Title: Placebo Effect Helps Some Psoriasis PatientsCategory: Health NewsCreated: 12/30/2009 12:10:00 PMLast Editorial Review: 12/31/2009 (Source: MedicineNet Skin General)

Placebo Effect Helps Some Psoriasis Patients

MedlinePlus Health News — Wed, 30 Dec 2009 17:00:00 +0100

Researchers hope to harness mind's reaction to medication Source: HealthDay Related MedlinePlus Topic: Psoriasis (Source: MedlinePlus Health News)

[Organizing pneumonia associated with psoriasis.]

Archivos de Bronconeumologia — Tue, 29 Dec 2009 00:00:00 +0100

Authors: Penizzotto M, Retegui M, Arrién Zucco MF PMID: 20044196 [PubMed - as supplied by publisher] (Source: Archivos de Bronconeumologia)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Study Redefines Placebo Effect as Part of Effective Treatment

Drugs.com - Clinical Trials — Mon, 28 Dec 2009 23:55:08 +0100

It's not Drug or Placebo; It's Drug and Placebo ROCHESTER, N.Y., Dec. 22 /PRNewswire-USNewswire/ -- Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely... (Source: Drugs.com - Clinical Trials)

Pediatric psoriasis increases with increasing age

MedWire News - Pediatrics — Fri, 25 Dec 2009 14:51:47 +0100

The incidence of pediatric psoriasis has increased over recent years, say researchers whose study also refutes the hypothesis that there is a dual peak in psoriasis incidence. (Source: MedWire News - Pediatrics)

Pediatric psoriasis increases with increasing age

MedWire News - Psoriasis — Fri, 25 Dec 2009 13:59:40 +0100

Apolipoprotein epsilon4 allele and psoriasis severity

Archives of Dermatological Research — Fri, 25 Dec 2009 00:17:39 +0100

Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00403-009-1016-9Authors Viroj Wiwanitkit, Wiwanitkit House, Bangkhae Bangkok 10160 Thailand Journal Archives of Dermatological ResearchOnline ISSN 1432-069XPrint ISSN 0340-3696 (Source: Archives of Dermatological Research)

Pediatric psoriasis increases with increasing age

MedWire News - Dermatology — Fri, 25 Dec 2009 00:00:00 +0100

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

British Journal of Pharmacology — Fri, 25 Dec 2009 00:00:00 +0100

Conclusions and implications: Apremilast displayed a broad pattern of anti-inflammatory activity in a variety of cell types and decreased the incidence and severity of a psoriasiform response in vivo. Inhibition of TNF-[alpha], IL-12 and IL-23 production, as well as NK and keratinocyte responses by this phosphodiesterase-4 inhibitor suggests a novel approach to the treatment of psoriasis. (Source: British Journal of Pharmacology)

Further association analysis of chr 6q22-24 suggests a role of IL-20RA polymorphisms in psoriasis

Journal of Dermatological Science — Thu, 24 Dec 2009 14:00:26 +0100

In our previous studies we obtained evidence that the interleukin-19 (IL19) gene cluster and interleukin-20 receptor alpha (IL20RA) gene may represent susceptibility regions for psoriasis . The aim of the present study was to scan an additional set of single nucleotide polymorphisms (SNPs) in the chromosomal region 6q22-24, which contains IL20RA, the genes for interleukin-22 receptor alpha 2 (IL22RA2) and interferon-gamma receptor 1 (IFNGR1) for association with psoriasis. (Source: Journal of Dermatological Science)

The vascular endothelial growth factor +405 G/C polymorphism in psoriasis

Journal of Dermatological Science — Thu, 24 Dec 2009 14:00:25 +0100

Psoriasis is a chronic inflammatory disorder of the skin keratinocytes, involving the expansion and dilation of superficial dermal microvasculature. Both genetic and environmental factors have important roles in the development of the disease. Angiogenesis has been indicated as a common and important pathogenic component in psoriasis, and VEGF, being a key contributor to angiogenesis, was further considered. Several studies have demonstrated that VEGF expression levels were increased in the sera of psoriasis patients , and that VEGF serum levels were directly correlated with disease activity . Keratin14-VEGF (VEGF driven by K14 gene promoter) transgenic mice developed inflammatory skin lesion with many cellular and molecular features mimic psoriasis . (Source: Journal of Dermatological Sci...

In vivo characterization of the structure and components of lesional psoriatic skin from the observation with Raman spectroscopy and optical coherence tomography: A pilot study

Journal of Dermatological Science — Thu, 24 Dec 2009 14:00:25 +0100

Psoriasis is a chronic, immuno-inflammatory disorder characterised by acanthosis with disturbed keratinocyte differentiation. The stratum corneum (SC) in psoriatic lesional skin is thick and histopathologically composed of parakeratotic cells. A changed lipid pattern of the SC has been observed in lesional skin . However, ceramide profiles in clinically normal psoriatic skin were comparable to those of healthy skin . As the clinical diagnosis of psoriasis is simple, most dermatologists tend to rely on the traditional visual subjective assessments . However, such assessments may still lack objectivity. Recently, commercially available instruments have been used for the objective assessment of psoriasis. Poor hydration state and barrier function in the involved areas were reported . Differen...

Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients

Journal of Dermatological Science — Thu, 24 Dec 2009 14:00:24 +0100

Conclusions: FOXP3 polymorphisms appear to contribute to the risk of psoriasis in a Han Chinese population. Larger studies are needed to confirm these findings. (Source: Journal of Dermatological Science)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Recovery from tanning induced by narrow-band UVB phototherapy in brown-skinned individuals with psoriasis: Twelve-month follow-up

Journal of Dermatological Science — Thu, 24 Dec 2009 14:00:23 +0100

Conclusion: Understanding the recovery process from tanning induced by NBUVB treatment will improve the patient's compliance for treatment and bring higher efficacy and safety to the retrial of phototherapy in brown-skinned individuals with psoriasis. (Source: Journal of Dermatological Science)

Apolipoprotein E4 and psoriasis

Archives of Dermatological Research — Wed, 23 Dec 2009 22:21:06 +0100

Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00403-009-1015-xAuthors Hong-Liang Zhang, The First Hospital of Jilin University Department of Neurology Changchun ChinaJiang Wu, The First Hospital of Jilin University Department of Neurology Changchun China Journal Archives of Dermatological ResearchOnline ISSN 1432-069XPrint ISSN 0340-3696 (Source: Archives of Dermatological Research)

Genomic differences identified in common skin diseases

The Rockefeller University Newswire — Wed, 23 Dec 2009 20:30:00 +0100

If you have dry skin, wet it, if wet skin, dry it. This has been a general rule of dermatology for centuries, but scientists are working to develop more precise treatments for the dozen-plus inflammatory skin diseases that afflict people. New research details the fine genetic and immunological differences between two of the most common skin diseases, psoriasis and atopic eczema, presenting a new way to classify the disorders as well as possible novel therapeutics. (Source: The Rockefeller University Newswire)

Drug and placebo: Study redefines placebo effect as part of effective treatment

ScienceDaily Headlines — Wed, 23 Dec 2009 15:43:14 +0100

Researchers used the placebo effect to successfully treat psoriasis patients with one quarter to one half of their usual dose of a widely used steroid medication, according to a new study. Early results in human patients suggest that the new technique could improve treatment for several chronic diseases that involve mental state or the immune system, including asthma, multiple sclerosis and chronic pain. (Source: ScienceDaily Headlines)